These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

583 related items for PubMed ID: 27040815

  • 1. A small molecule nanodrug consisting of amphiphilic targeting ligand-chemotherapy drug conjugate for targeted cancer therapy.
    Mou Q, Ma Y, Zhu X, Yan D.
    J Control Release; 2016 May 28; 230():34-44. PubMed ID: 27040815
    [Abstract] [Full Text] [Related]

  • 2. Fullerene (C60)-based tumor-targeting nanoparticles with "off-on" state for enhanced treatment of cancer.
    Shi J, Wang B, Wang L, Lu T, Fu Y, Zhang H, Zhang Z.
    J Control Release; 2016 Aug 10; 235():245-258. PubMed ID: 27276066
    [Abstract] [Full Text] [Related]

  • 3. A novel high drug loading mussel-inspired polydopamine hybrid nanoparticle as a pH-sensitive vehicle for drug delivery.
    Hou J, Guo C, Shi Y, Liu E, Dong W, Yu B, Liu S, Gong J.
    Int J Pharm; 2017 Nov 25; 533(1):73-83. PubMed ID: 28943209
    [Abstract] [Full Text] [Related]

  • 4. pH-sensitive small molecule nanodrug self-assembled from amphiphilic vitamin B6-E analogue conjugate for targeted synergistic cancer therapy.
    Yan G, Chen R, Xiong N, Song J, Wang X, Tang R.
    Colloids Surf B Biointerfaces; 2020 Jul 25; 191():111000. PubMed ID: 32247946
    [Abstract] [Full Text] [Related]

  • 5. Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo.
    Qiu M, Sun H, Meng F, Cheng R, Zhang J, Deng C, Zhong Z.
    J Control Release; 2018 Feb 28; 272():107-113. PubMed ID: 29355618
    [Abstract] [Full Text] [Related]

  • 6. Surface-Modified Nanoerythrocyte Loading DOX for Targeted Liver Cancer Chemotherapy.
    Wang Y, Chen X, He D, Zhou Y, Qin L.
    Mol Pharm; 2018 Dec 03; 15(12):5728-5740. PubMed ID: 30359027
    [Abstract] [Full Text] [Related]

  • 7. Stepwise pH-responsive nanoparticles for enhanced cellular uptake and on-demand intracellular release of doxorubicin.
    Chen WL, Li F, Tang Y, Yang SD, Li JZ, Yuan ZQ, Liu Y, Zhou XF, Liu C, Zhang XN.
    Int J Nanomedicine; 2017 Dec 03; 12():4241-4256. PubMed ID: 28652730
    [Abstract] [Full Text] [Related]

  • 8. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy.
    Li W, Yi X, Liu X, Zhang Z, Fu Y, Gong T.
    J Control Release; 2016 Mar 10; 225():170-82. PubMed ID: 26826304
    [Abstract] [Full Text] [Related]

  • 9. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A, Salmaso S, Eldar-Boock A, Ben-Shushan D, Ferber S, Tiram G, Shmeeda H, Landa-Rouben N, Leor J, Caliceti P, Gabizon A, Satchi-Fainaro R.
    J Control Release; 2015 Jun 28; 208():106-20. PubMed ID: 25869964
    [Abstract] [Full Text] [Related]

  • 10. Novel, Self-Distinguished, Dual Stimulus-Responsive Therapeutic Nanoplatform for Intracellular On-Demand Drug Release.
    Sun H, Fan Z, Xiang S, Zuo W, Yang Y, Huang D, Su G, Fu X, Zhao Q, Hou Z.
    Mol Pharm; 2020 Jul 06; 17(7):2435-2450. PubMed ID: 32459486
    [Abstract] [Full Text] [Related]

  • 11. Self-crosslinkable and intracellularly decrosslinkable biodegradable micellar nanoparticles: A robust, simple and multifunctional nanoplatform for high-efficiency targeted cancer chemotherapy.
    Zou Y, Fang Y, Meng H, Meng F, Deng C, Zhang J, Zhong Z.
    J Control Release; 2016 Dec 28; 244(Pt B):326-335. PubMed ID: 27245309
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Bioreducible core-crosslinked hyaluronic acid micelle for targeted cancer therapy.
    Han HS, Choi KY, Ko H, Jeon J, Saravanakumar G, Suh YD, Lee DS, Park JH.
    J Control Release; 2015 Feb 28; 200():158-66. PubMed ID: 25550153
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Insight into the role of dual-ligand modification in low molecular weight heparin based nanocarrier for targeted delivery of doxorubicin.
    Du H, Liu M, Yu A, Ji J, Zhai G.
    Int J Pharm; 2017 May 15; 523(1):427-438. PubMed ID: 28359815
    [Abstract] [Full Text] [Related]

  • 16. Galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma.
    Xia Y, Zhong J, Zhao M, Tang Y, Han N, Hua L, Xu T, Wang C, Zhu B.
    Drug Deliv; 2019 Dec 15; 26(1):1-11. PubMed ID: 31928356
    [Abstract] [Full Text] [Related]

  • 17. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
    Lv S, Li M, Tang Z, Song W, Sun H, Liu H, Chen X.
    Acta Biomater; 2013 Dec 15; 9(12):9330-42. PubMed ID: 23958784
    [Abstract] [Full Text] [Related]

  • 18. Doxorubicin/heparin composite nanoparticles for caspase-activated prodrug chemotherapy.
    Khaliq NU, Sandra FC, Park DY, Lee JY, Oh KS, Kim D, Byun Y, Kim IS, Kwon IC, Kim SY, Yuk SH.
    Biomaterials; 2016 Sep 15; 101():131-42. PubMed ID: 27286189
    [Abstract] [Full Text] [Related]

  • 19. Multifunctional hollow nanoparticles based on graft-diblock copolymers for doxorubicin delivery.
    Lu PL, Chen YC, Ou TW, Chen HH, Tsai HC, Wen CJ, Lo CL, Wey SP, Lin KJ, Yen TC, Hsiue GH.
    Biomaterials; 2011 Mar 15; 32(8):2213-21. PubMed ID: 21176954
    [Abstract] [Full Text] [Related]

  • 20. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y, Zhang J, Cheng R, Deng C, Meng F, Xie F, Zhong Z.
    J Control Release; 2015 May 10; 205():144-54. PubMed ID: 25596560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.